Radiopharm TheranosticsRADX
13F holders, Q1 2025 (March 31)3holders −1
0new positions
1sold out
$4.81avg. 13F price*
At the end of Q1 2025, 3 institutions reported holding Radiopharm Theranostics Ltd. (RADX) in their 13F filings, down 1 from Q4 2024. 0 opened new positions and 1 sold out. The largest holders were Silverarc Capital Management, LLC ($901K), Regal Partners Ltd ($437K) and Affinity Asset Advisors, LLC ($311K).
- Company
- Radiopharm Theranostics Ltd.
- CUSIP
- 75041J101
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $6K |
All 13F filers, Q4 2024 → Q1 2025: 92,888 shares sold, net −92,888 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Silverarc Capital Management, LLC | 0.19% | No change | 187,406 | $901K |
| Regal Partners Ltd | 0.04% | No change | 90,909 | $437K |
| Affinity Asset Advisors, LLC | 0.05% | Reduce -58.6% | 64,600 | $311K |
"% of holder's portfolio" is RADX's weight in each manager's 13F, not the share of Radiopharm Theranostics Ltd. the manager owns.